【大行评级｜中银国际：上调康方生物目标价至87港元预计今年实现盈亏平衡】中银国际发表报告指，康方生物去年扣除分销成本后的商业销售额为20亿元，按年增长24.9%，基本符合市场预期。净亏损为5.011亿元，好于该行预期，表明康方生物的执行能力和成本控制工作。今年值得关注的关键是年中的AK112在 1LPD-L1+非小细胞肺癌中的上市批准和在 HARMONi 海外数据公布。业绩公布后，该行下调2025-26年收入预测，主要是因为AK104(纳入国家医保目录后降价)和 AK105(合作伙伴商业化战略变化)的销售贡献下降。该行下调了核心产品降价后的毛利率，预计将在今年实现盈亏平衡，目标价上调至87港元，重申“买入”评级。

金融界

01 Apr

中银国际发表报告指，康方生物去年扣除分销成本后的商业销售额为20亿元，按年增长24.9%，基本符合市场预期。净亏损为5.011亿元，好于该行预期，表明康方生物的执行能力和成本控制工作。今年值得关注的关键是年中的AK112在 1LPD-L1+非小细胞肺癌中的上市批准和在 HARMONi 海外数据公布。业绩公布后，该行下调2025-26年收入预测，主要是因为AK104(纳入国家医保目录后降价)和 AK105(合作伙伴商业化战略变化)的销售贡献下降。该行下调了核心产品降价后的毛利率，预计将在今年实现盈亏平衡，目标价上调至87港元，重申“买入”评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2524396111"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524396111\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2524396111?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-04-01 12:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524396111","market":"sh","top_or_hot":-1,"title":"【大行评级｜中银国际：上调康方生物目标价至87港元 预计今年实现盈亏平衡】中银国际发表报告指，康方生物去年扣除分销成本后的商业销售额为20亿元，按年增长24.9%，基本符合市场预期。净亏损为5.011亿元，好于该行预期，表明康方生物的执行能力和成本控制工作。今年值得关注的关键是年中的AK112在 1LPD-L1+非小细胞肺癌中的上市批准和在 HARMONi 海外数据公布。业绩公布后，该行下调2025-26年收入预测，主要是因为AK104(纳入国家医保目录后降价)和 AK105(合作伙伴商业化战略变化)的销售贡献下降。该行下调了核心产品降价后的毛利率，预计将在今年实现盈亏平衡，目标价上调至87港元，重申“买入”评级。","media":"金融界","content":"<html><body><div>中银国际发表报告指，<a href=\"https://laohu8.com/S/09926\">康方生物</a>去年扣除分销成本后的商业销售额为20亿元，按年增长24.9%，基本符合市场预期。净亏损为5.011亿元，好于该行预期，表明康方生物的执行能力和成本控制工作。今年值得关注的关键是年中的AK112在 1LPD-L1+非小细胞肺癌中的上市批准和在 HARMONi 海外数据公布。业绩公布后，该行下调2025-26年收入预测，主要是因为AK104(纳入国家医保目录后降价)和 AK105(合作伙伴商业化战略变化)的销售贡献下降。该行下调了核心产品降价后的毛利率，预计将在今年实现盈亏平衡，目标价上调至87港元，重申“买入”评级。</div></body></html>","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【大行评级｜中银国际：上调康方生物目标价至87港元 预计今年实现盈亏平衡】中银国际发表报告指，康方生物去年扣除分销成本后的商业销售额为20亿元，按年增长24.9%，基本符合市场预期。净亏损为5.011亿元，好于该行预期，表明康方生物的执行能力和成本控制工作。今年值得关注的关键是年中的AK112在 1LPD-L1+非小细胞肺癌中的上市批准和在 HARMONi 海外数据公布。业绩公布后，该行下调2025-26年收入预测，主要是因为AK104(纳入国家医保目录后降价)和 AK105(合作伙伴商业化战略变化)的销售贡献下降。该行下调了核心产品降价后的毛利率，预计将在今年实现盈亏平衡，目标价上调至87港元，重申“买入”评级。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【大行评级｜中银国际：上调康方生物目标价至87港元 预计今年实现盈亏平衡】中银国际发表报告指，康方生物去年扣除分销成本后的商业销售额为20亿元，按年增长24.9%，基本符合市场预期。净亏损为5.011亿元，好于该行预期，表明康方生物的执行能力和成本控制工作。今年值得关注的关键是年中的AK112在 1LPD-L1+非小细胞肺癌中的上市批准和在 HARMONi 海外数据公布。业绩公布后，该行下调2025-26年收入预测，主要是因为AK104(纳入国家医保目录后降价)和 AK105(合作伙伴商业化战略变化)的销售贡献下降。该行下调了核心产品降价后的毛利率，预计将在今年实现盈亏平衡，目标价上调至87港元，重申“买入”评级。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-01 12:12 北京时间&nbsp;&nbsp;&nbsp;<a href=https://24h.jrj.com.cn/2025/04/01121249200597.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中银国际发表报告指，康方生物去年扣除分销成本后的商业销售额为20亿元，按年增长24.9%，基本符合市场预期。净亏损为5.011亿元，好于该行预期，表明康方生物的执行能力和成本控制工作。今年值得关注的关键是年中的AK112在 1LPD-L1+非小细胞肺癌中的上市批准和在 HARMONi 海外数据公布。业绩公布后，该行下调2025-26年收入预测，主要是因为AK104(纳入国家医保目录后降价)和 ...</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/04/01121249200597.shtml\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://24h.jrj.com.cn/2025/04/01121249200597.shtml","article_id":"2524396111","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524396111","pubTimestamp":1743480761,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"中银国际发表报告指，康方生物去年扣除分销成本后的商业销售额为20亿元，按年增长24.9%，基本符合市场预期。净亏损为5.011亿元，好于该行预期，表明康方生物的执行能力和成本控制工作。今年值得关注的关键是年中的AK112在 1LPD-L1+非小细胞肺癌中的上市批准和在 HARMONi 海外数据公布。业绩公布后，该行下调2025-26年收入预测，主要是因为AK104(纳入国家医保目录后降价)和 AK105(合作伙伴商业化战略变化)的销售贡献下降。该行下调了核心产品降价后的毛利率，预计将在今年实现盈亏平衡，目标价上调至87港元，重申“买入”评级。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{},"translate_title":"[Big Bank Rating | BOC International: Raised the target price of Akeso to HK $87 and expected to achieve breakeven this year] BOC International issued a report stating that Akeso's commercial sales after deducting distribution costs last year were 2 billion yuan, a year-on-year increase of 24.9%, basically in line with market expectations. The net loss was 501.1 million yuan, which was better than the bank's expectations, indicating Akeso's execution capabilities and cost control work. The key points worthy of attention this year are the marketing approval of AK112 in 1LPD-L1 + non-small cell ","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"中银国际发表报告指，康方生物去年扣除分销成本后的商业销售额为20亿元，按年增长24.9%，基本符合市场预期。净亏损为5.011亿元，好于该行预期，表明康方生物的执行能力和成本控制工作。今年值得关注的关键是年中的AK112在 1LPD-L1+非小细胞肺癌中的上市批准和在 HARMONi 海外数据公布。业绩公布后，该行下调2025-26年收入预测，主要是因为AK104(纳入国家医保目录后降价)和 AK105(合作伙伴商业化战略变化)的销售贡献下降。该行下调了核心产品降价后的毛利率，预计将在今年实现盈亏平衡，目标价上调至87港元，重申“买入”评级。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}